التفاصيل البيبلوغرافية
| العنوان: |
The Prognostic Impact of Determining Treatment Plans Based on Discordant Metastatic Tumor Receptors on Relapse. |
| المؤلفون: |
Pannell Jr, T. Allen, Panella, Timothy J., Zaretzki, R. L. |
| المصدر: |
American Journal of Hematology/Oncology; Sep2016, Vol. 12 Issue 9, p14-20, 7p |
| مصطلحات موضوعية: |
BREAST tumor treatment, ACADEMIC medical centers, CANCER patients, CANCER relapse, CELL receptors, LIFE expectancy, MEDICAL records, METASTASIS, SCIENTIFIC observation, HEALTH outcome assessment, SURVIVAL analysis (Biometry), LITERATURE reviews, RETROSPECTIVE studies, DESCRIPTIVE statistics, SECONDARY primary cancer, ACQUISITION of data methodology, LOG-rank test |
| مصطلحات جغرافية: |
UNITED States |
| مستخلص: |
Background: For over 2 decades, breast cancer researchers have studied the clinical importance of testing the receptor status of metastatic tumors. Little evidence suggests that treatment plans based on metastatic tumor receptor status test results improve the clinical outcomes of patients. In fact, evidence exists that changes to treatment plans based on this retesting, when discordant, are harmful to patient outcomes. Methods: A literature review evaluated the current state of evidence regarding treatment plans based on the retest results of metastatic tumors when different from the primary tumor. A retrospective observational study was designed to validate the literature findings. Data from the University of Tennessee Cancer Institute was queried for patients with recurrent metastatic breast cancer (MBC) from 2000 to 2014, yielding 124 complete and relevant recurrent MBC records. Of the 124 patients, 92 cases had the receptor status of their metastatic tumor evaluated. Fourteen patients' receptor status were discordant with their primary tumors. Eight of these patients' first-line treatment plans were based on the primary tumor receptor status, and 6 patients' first-line treatment plans were based on the receptor status of their metastatic tumors. Results: The sample revealed that MBC patients with discordant receptor results, whose first-line treatment plan was based on their primary tumors, had additional median survival of 40 months, with a P value of .049 utilizing the logrank test. No other published research has explicitly made such a comparison. Conclusions: This study indicates that first-line treatment plans for patients with MBC based on the receptor status of the primary tumor instead of the metastatic tumor extends life expectancy of patients. This research could impact the lives of 6000 women with MBC per year in the United States. [ABSTRACT FROM AUTHOR] |
|
Copyright of American Journal of Hematology/Oncology is the property of Physicians' Education Resource, LLC and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
